We obtained the chemical structure for plogosertib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a serine/threonine kinase inhibitor and antineoplastic. This Chemical structure mapped to PubChem CID 42640739, and compound 384 as claimed in patent WO2009040556A1 (Cyclacel Limited) which claims pyrimidine derivatives as inhibitors of kinases, 'particularly polo-like kinases' [1
]. Plogosertib could be CYC140, Cyclacel's PLK1 clinical lead candidate. Cancer cells with mutated KRAS or p53(-) cells are sensitive to PLK1 inhibition. In these cells it induces prolonged mitotic arrest and apoptosis.